Curative surgery for Small-Cell Lung Cancer (SCLCs) is rare, accounting for less than 5 % of surgeries for bronchopulmonary cancer. The rapid progression of SCLCs and their discovery at a metastatic or locally advanced stage generally exclude them from surgical strategy. Even in localized tumor forms, this surgery is rarely proposed. However, scientific societies (ASCO, ESMO, INCA) have established multimodal management recommendations including radical surgery for selected patients, despite very low levels of evidence. This primarily concerns stage I and sometimes stage II patients, if adjuvant chemotherapy is feasible. Including surgery, the median survival for stage I patients ranges from 28 to 54 months, and 5-year survival rates from 34 % to 65 %, values significantly higher than for non-operated patients. This surgery is not suitable for multi-site or “bulky” N2, but some N2 patients appear to benefit with 5-year survival rates exceeding 20 %. Salvage surgery after tumor re-evolution is possible under certain conditions. Lobectomy with lymph node dissection is the preferred intervention in this context, and the role of sub-lobar resection remains controversial. All these results justify medical combined to surgical discussions in Thoracic Oncology multidisciplinary tumor board for these SCLC patients. Thanks to screening programs and improved staging assessments, the more frequent diagnosis of less extensive forms will certainly highlight the role of surgery for SCLCs. 1877-1203/© 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.